Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty
NCT03169231 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150
Last updated 2022-03-07
Summary
This is a randomized, placebo-controlled, double-blind, parallel arm, multi-center Phase 2b study.
Conditions
- Aging Frailty
Interventions
- BIOLOGICAL
-
Longeveron Mesenchymal Stem Cells (LMSCs)
Intravenously delivered
- OTHER
-
Placebo
Intravenously delivered
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 70 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-07-06
- Primary Completion
- 2021-09-30
- Completion
- 2021-09-30
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
NCT03268603 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Mitophagy and Autophagy in Elderly Subjects
NCT02472340 ·Status: COMPLETED
-
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT02579239 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
NCT06100276 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells
NCT02213705 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)
NCT02013700 ·Status: TERMINATED ·Phase: PHASE1
-
Neurologic Stem Cell Treatment Study
NCT02795052 ·Status: RECRUITING ·Phase: NA
-
Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)
NCT01142856 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
NCT02017912 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
NCT05230459 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis
NCT01363401 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT06547216 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients
NCT03280056 ·Status: COMPLETED ·Phase: PHASE3
-
A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis
NCT01609283 ·Status: COMPLETED ·Phase: PHASE1
-
Frontline Lenalidomide for AL Amyloidosis Involving Myocardium
NCT04298372 ·Status: COMPLETED ·Phase: PHASE3
-
Long-Term Development of Muscular Dystrophy Outcome Assessments
NCT05989620 ·Status: RECRUITING
-
Study of Efficacy and Safety of AVTR101 in Sarcopenic Elderly
NCT06788236 ·Status: TERMINATED ·Phase: PHASE2
-
A Diagnostic Test for Dementia With Lewy Bodies
NCT05479552 ·Status: ACTIVE_NOT_RECRUITING
-
ALS Reversals - Lunasin Regimen
NCT02709330 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT05747924 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis
NCT02116634 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy
NCT06288230 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
NCT06292780 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)
NCT02628743 ·Status: COMPLETED ·Phase: PHASE2
-
hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases
NCT06607900 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1